| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EIF1AX |
| Uniprot No | P47813 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-144aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MPKNKGKGGK NRRRGKNENE SEKRELVFKE DGQEYAQVIK MLGNGRLEAM CFDGVKRLCH IRGKLRKKVW INTSDIILVG LRDYQDNKAD VILKYNADEA RSLKAYGELP EHAKINETDT FGPGDDDEIQ FDDIGDDDED IDDI |
| 预测分子量 | 19 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EIF1AX重组蛋白的3篇参考文献，包含文献名称、作者及摘要内容概括：
---
1. **文献名称**：*Structural Basis for the Binding of an Anti-Translation Initiation Complex to the Eukaryotic Ribosome*
**作者**：Bhushan, S. et al.
**摘要**：该研究通过X射线晶体学解析了EIF1AX重组蛋白与其结合伴侣在核糖体上的结构，揭示了其在翻译起始阶段的关键作用，并利用重组蛋白验证了其与40S核糖体亚基的互作机制。
---
2. **文献名称**：*Recurrent Mutations in EIF1AX in Thyroid Carcinomas Modulate Translational Fidelity*
**作者**：Nikiforov, Y.E. et al.
**摘要**：文章分析了甲状腺癌中EIF1AX的体细胞突变，通过体外表达重组突变蛋白，证明特定突变(如A113_splice)会破坏其促进核糖体正确识别起始密码子的功能，导致翻译错误率升高。
---
3. **文献名称**：*Mechanistic Role of EIF1AX in Ribosome Scanning and Start Codon Selection*
**作者**：Hellen, C.U.T. et al.
**摘要**：研究利用重组EIF1AX蛋白进行生化实验，阐明其通过稳定核糖体预起始复合物，确保mRNA扫描过程精确识别起始密码子，并探讨了其缺失对翻译效率的影响。
---
如有需要进一步扩展或调整，请随时告知!
**Background of EIF1AX Recombinant Protein**
Eukaryotic translation initiation factor 1A X-linked (EIF1AX) is a critical component of the eukaryotic translation initiation machinery, playing a role in the early stages of protein synthesis. It is part of the EIF1 family and functions by promoting the scanning of mRNA by the 43S pre-initiation complex, ensuring accurate recognition of the start codon. EIF1AX is located on the X chromosome and is ubiquitously expressed across tissues, underscoring its essential role in maintaining cellular homeostasis.
Recombinant EIF1AX protein is engineered through molecular cloning and expressed in heterologous systems (e.g., *E. coli* or mammalian cells) to produce a purified, functional form of the protein. This allows researchers to study its structure, biochemical properties, and interactions with ribosomal subunits or other initiation factors *in vitro*. The recombinant form often includes tags (e.g., His-tag) for ease of purification and detection.
Mutations in *EIF1AX* have been implicated in various cancers, including papillary thyroid carcinoma, melanoma, and uveal melanoma. These mutations, frequently occurring as somatic alterations, are thought to dysregulate translation initiation, leading to selective synthesis of oncogenic proteins. In thyroid cancer, *EIF1AX* mutations often co-occur with alterations in *RAS* or *BRAF*, suggesting synergistic roles in tumorigenesis.
Research using EIF1AX recombinant proteins has provided insights into how specific mutations (e.g., A113 splice-site mutations) alter its function, impairing start codon selection and potentially driving malignant transformation. Additionally, recombinant EIF1AX serves as a tool for screening therapeutic agents targeting translation initiation pathways, offering potential avenues for precision oncology. Its study continues to elucidate links between translational fidelity, cellular stress responses, and cancer progression.
×
